CONMED Corporation Promotes Patrick Beyer to Chief Operating Officer

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Patrick Beyer, President of International and Global Orthopedics, has been promoted to the newly created role of Chief Operating Officer (COO), effective immediately. In this role, Mr. Beyer will take on additional responsibility for leading the Company’s commercial businesses, as well as Operations, Distribution, Regulatory Affairs / Quality Assurance, and Customer Excellence.

“Pat has been invaluable in driving CONMED’s above-market growth and expanding our presence in key markets,” commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer. “He is an experienced leader with a proven track record of commercial and operational excellence and delivering results, and I look forward to Pat’s continued impact on the organization.”

“I am excited to take on this important leadership role at CONMED and to continue contributing to the Company’s innovation and success,” said Mr. Beyer. “I look forward to continuing to work with the team to build on CONMED’s legacy of delivering high-quality products and creating value for physicians and patients around the world.”

Mr. Beyer joined CONMED in 2014 as President of International. In October 2020, Mr. Beyer was promoted to President of International and Global Orthopedics, where he took on the added responsibilities for the Company’s Global Orthopedics R&D and U.S. Orthopedics commercial business. In 2022, Mr. Beyer led the process of acquiring both In2Bones and BioRez. Prior to CONMED, Mr. Beyer spent 21 years at Stryker in leadership roles of increasing progression and nearly four years as CEO of ICNet International. He holds a B.A. in Economics from Kalamazoo College and an M.B.A from Western Michigan University. Mr. Beyer also completed the Advanced Management Program at Harvard University.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2023, and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.